Are Circulating Immune Cells a Determinant of Pancreatic Cancer Risk? A Prospective Study Using Epigenetic Cell Count Measures.


Journal

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608

Informations de publication

Date de publication:
12 2021
Historique:
received: 09 02 2021
revised: 17 05 2021
accepted: 03 09 2021
pubmed: 23 9 2021
medline: 5 3 2022
entrez: 22 9 2021
Statut: ppublish

Résumé

Evidence is accumulating that immune cells play a prominent role in pancreatic cancer etiology but prospective investigations are missing. We conducted a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) study with 502 pairs of incident pancreatic cancer cases and matched controls. Relative counts of circulating immune cells (neutrophils and lymphocyte sublineages: total CD3 Neither relative counts of immune cell types taken individually, nor mutually adjusted for each other were associated with pancreatic cancer risks. However, in subgroup analyses by strata of lag-time, higher relative counts of Tregs and lower relative counts of CD8 These results might reflect reverse causation, due to higher relative counts of Tregs and lower counts of CD8 We have shown, for the first time, that increased relative counts of regulatory T cells and lower relative counts of CD8

Sections du résumé

BACKGROUND
Evidence is accumulating that immune cells play a prominent role in pancreatic cancer etiology but prospective investigations are missing.
METHODS
We conducted a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) study with 502 pairs of incident pancreatic cancer cases and matched controls. Relative counts of circulating immune cells (neutrophils and lymphocyte sublineages: total CD3
RESULTS
Neither relative counts of immune cell types taken individually, nor mutually adjusted for each other were associated with pancreatic cancer risks. However, in subgroup analyses by strata of lag-time, higher relative counts of Tregs and lower relative counts of CD8
CONCLUSIONS
These results might reflect reverse causation, due to higher relative counts of Tregs and lower counts of CD8
IMPACT
We have shown, for the first time, that increased relative counts of regulatory T cells and lower relative counts of CD8

Identifiants

pubmed: 34548327
pii: 1055-9965.EPI-21-0169
doi: 10.1158/1055-9965.EPI-21-0169
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2179-2187

Subventions

Organisme : Medical Research Council
ID : MR/N003284/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000143
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 14136
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M012190/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0401527
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C570/A16491
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

©2021 American Association for Cancer Research.

Références

Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007;67:9518–27.
Huber M, Brehm CU, Gress TM, Buchholz M, Alashkar Alhamwe B, von Strandmann EP, et al. The immune microenvironment in pancreatic cancer. Int J Mol Sci. 2020;21:7307.
Inman KS, Francis AA, Murray NR. Complex role for the immune system in initiation and progression of pancreatic cancer. World J Gastroenterol. 2014;20:11160–81.
Karamitopoulou E. Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features. Br J Cancer. 2019;121:5–14.
Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 2004;28:e26–31.
Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer. 2013;108:914–23.
Ikemoto T, Yamaguchi T, Morine Y, Imura S, Soejima Y, Fujii M, et al. Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients. Pancreas. 2006;33:386–90.
Yamamoto T, Yanagimoto H, Satoi S, Toyokawa H, Hirooka S, Yamaki S, et al. Circulating CD4+CD25+ regulatory T cells in patients with pancreatic cancer. Pancreas. 2012;41:409–15.
Karakhanova S, Ryschich E, Mosl B, Harig S, Jager D, Schmidt J, et al. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. Br J Cancer. 2015;112:1027–36.
Arima K, Okabe H, Hashimoto D, Chikamoto A, Tsuji A, Yamamura K, et al. The diagnostic role of the neutrophil-to-lymphocyte ratio in predicting pancreatic ductal adenocarcinoma in patients with pancreatic diseases. Int J Clin Oncol. 2016;21:940–5.
Guo W, Lu X, Liu Q, Zhang T, Li P, Qiao W, et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: an updated meta-analysis of 17079 individuals. Cancer Med. 2019;8:4135–48.
Mei Z, Shi L, Wang B, Yang J, Xiao Z, Du P, et al. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: a systematic review and meta-analysis of 66 cohort studies. Cancer Treat Rev. 2017;58:1–13.
Baron U, Werner J, Schildknecht K, Schulze JJ, Mulu A, Liebert UG, et al. Epigenetic immune cell counting in human blood samples for immunodiagnostics. Sci Transl Med. 2018;10:eaan3508.
Le Cornet C, Schildknecht K, Rossello Chornet A, Fortner RT, Gonzalez Maldonado S, Katzke VA, et al. Circulating immune cell composition and cancer risk: a prospective study using epigenetic cell count measures. Cancer Res. 2020;80:1885–92.
Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5:1113–24.
Caboux E, Lallemand C, Ferro G, Hemon B, Mendy M, Biessy C, et al. Sources of pre-analytical variations in yield of DNA extracted from blood samples: analysis of 50,000 DNA samples in EPIC. PLoS One. 2012;7:e39821.
Baron U, Floess S, Wieczorek G, Baumann K, Grutzkau A, Dong J, et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol. 2007;37:2378–89.
Sehouli J, Loddenkemper C, Cornu T, Schwachula T, Hoffmuller U, Grutzkau A, et al. Epigenetic quantification of tumor-infiltrating T-lymphocytes. Epigenetics. 2011;6:236–46.
Singh A, Yamamoto M, Ruan J, Choi JY, Gauvreau GM, Olek S, et al. Th17/Treg ratio derived using DNA methylation analysis is associated with the late phase asthmatic response. Allergy Asthma Clin Immunol. 2014;10:32.
Baron U, Turbachova I, Hellwag A, Eckhardt F, Berlin K, Hoffmuller U, et al. DNA methylation analysis as a tool for cell typing. Epigenetics. 2006;1:55–60.
Schlittgen R. Analysis of incomplete multivariate data:. Comput Stat Data Anal. 1999;30:478–9.
Sakaguchi S, Wing K, Yamaguchi T. Dynamics of peripheral tolerance and immune regulation mediated by Treg. Eur J Immunol. 2009;39:2331–6.
Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133:775–87.
Orhan A, Vogelsang RP, Andersen MB, Madsen MT, Holmich ER, Raskov H, et al. The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis. Eur J Cancer. 2020;132:71–84.
Martinez-Bosch N, Vinaixa J, Navarro P. Immune evasion in pancreatic cancer: from mechanisms to therapy. Cancers. 2018;10:6.
Schnell A, Schmidl C, Herr W, Siska PJ. The peripheral and intratumoral immune cell landscape in cancer patients: a proxy for tumor biology and a tool for outcome prediction. Biomedicines. 2018;6:25.
Turbachova I, Schwachula T, Vasconcelos I, Mustea A, Baldinger T, Jones KA, et al. The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. Epigenetics. 2013;8:1226–35.
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565–70.
Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol. 2008;3:157–88.
Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371:1039–49.
Carnevale S, Ghasemi S, Rigatelli A, Jaillon S. The complexity of neutrophils in health and disease: focus on cancer. Semin Immunol. 2020;48:101409.
Liew PX, Kubes P. The neutrophil's role during health and disease. Physiol Rev. 2019;99:1223–48.
Tao L, Zhang L, Peng Y, Tao M, Li G, Xiu D, et al. Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict lymph node metastasis in patients with pancreatic ductal adenocarcinoma (PDAC). Oncotarget. 2016;7:74314–24.
Ben Q, An W, Wang L, Wang W, Yu L, Yuan Y. Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma. Pancreas. 2015;44:471–7.
Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor AJ. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020;18:360.
Yang JJ, Hu ZG, Shi WX, Deng T, He SQ, Yuan SG. Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis. World J Gastroenterol. 2015;21:2807–15.
Michaud DS, Ruan M, Koestler DC, Alonso L, Molina-Montes E, Pei D, et al. DNA methylation-derived immune cell profiles, CpG markers of inflammation, and pancreatic cancer risk. Cancer Epidemiol Biomarkers Prev. 2020;29:1577–85.

Auteurs

Verena A Katzke (VA)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. v.katzke@dkfz.de.

Charlotte Le Cornet (C)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Rayaan Mahfouz (R)

Ivana Türbachova Laboratory for Epigenetics, Epiontis GmbH, Berlin, Germany, Precision for Medicine Group.

Bianca Brauer (B)

Ivana Türbachova Laboratory for Epigenetics, Epiontis GmbH, Berlin, Germany, Precision for Medicine Group.

Theron Johnson (T)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Federico Canzian (F)

Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Vinciane Rebours (V)

Pancreatology Department, Beaujon Hospital, AP-HP, Clichy, France.
Inserm UMR1149, DHU Unit, Paris-Diderot University, Paris, France.

Marie-Christine Boutron-Ruault (MC)

Paris-Saclay University, UVSQ, Inserm, Gustave Roussy, "Exposome and Heredity" team, CESP, F-94805, Villejuif, France.

Gianluca Severi (G)

Paris-Saclay University, UVSQ, Inserm, Gustave Roussy, "Exposome and Heredity" team, CESP, F-94805, Villejuif, France.
Department of Statistics, Computer Science and Applications "G. Parenti," University of Florence, Florence, Italy.

Matthias B Schulze (MB)

Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany.

Anja Olsen (A)

Danish Cancer Society Research Center, Copenhagen, Denmark.
Department of Public Health, University of Århus, Århus, Denmark.

Anne Tjønneland (A)

Danish Cancer Society Research Center, Copenhagen, Denmark.
Department of Public Health, University of Copenhagen, Copenhagen, Denmark.

Kim Overvad (K)

Department of Public Health, University of Århus, Århus, Denmark.

Marta Crous-Bou (M)

Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet de Llobregat, Barcelona 08908, Spain.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Esther Molina-Montes (E)

Department of Nutrition and Food Sciences, Faculty of Pharmacy, University of Granada, Granada, Spain.
Instituto de Investigación Biosanitaria (ibs.GRANADA), Granada, Spain.
CIBERESP, Madrid, Spain.
Institute of Nutrition and Food Technology "José Mataix," Center of Biomedical Research, University of Granada, Granada, Spain.

Pilar Amiano (P)

CIBERESP, Madrid, Spain.
Public Health Division of Gipuzkoa, BioDonostia Research Institute, Donostia-San Sebastian, Spain.

José María Huerta (JM)

CIBERESP, Madrid, Spain.
Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain.

Eva Ardanaz (E)

CIBERESP, Madrid, Spain.
Navarra Public Health Institute, Pamplona, Spain.
IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.

Aurora Perez-Cornago (A)

Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford UK.

Giovanna Masala (G)

Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy.

Valeria Pala (V)

Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.

Rosario Tumino (R)

Cancer Registry and Histopathology Department, Provincial Health Authority (ASP 7) Ragusa, Italy.

Carlotta Sacerdote (C)

Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital, Turin, Italy.

Salvatore Panico (S)

Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy.

Bas Bueno-de-Mesquita (B)

Former senior scientist, Dept. for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720 BA Bilthoven, the Netherlands.

Roel Vermeulen (R)

Institute for Risk Assessment Sciences, Utrecht University, Utrecht, the Netherlands.
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
School of Public Health, Imperial College London, London, UK.

Malin Sund (M)

Department of Surgical and Perioperative Sciences, Umeå University, Sweden.

Oskar Franklin (O)

Department of Surgical and Perioperative Sciences, Umeå University, Sweden.

Sofia Christakoudi (S)

School of Public Health, Imperial College London, London, UK.
Department of Epidemiology and Biostatistics, Imperial College London, Norfolk Place, St Mary's Campus, London, United Kingdom.
MRC Centre for Transplantation, King's College London, Great Maze Pond, London, United Kingdom.

Laure Dossus (L)

International Agency for Research on Cancer, World Health Organization, Lyon, France.

Elisabete Weiderpass (E)

Director, International Agency for Research on Cancer, World Health Organization, Lyon, France.

Sven Olek (S)

Ivana Türbachova Laboratory for Epigenetics, Epiontis GmbH, Berlin, Germany, Precision for Medicine Group.

Rudolf Kaaks (R)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Translational Lung Research Center (TLRC) Heidelberg, Member of the German Center for Lung Research (DZL), Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH